Effect of dronedarone versus amiodarone on the risk of bleeding in non-valvular atrial fibrillation patients undergoing rivaroxaban anticoagulation
10.3760/cma.j.cn341190-20231109-00406
- VernacularTitle:决奈达隆与胺碘酮对利伐沙班抗凝非瓣膜性房颤患者出血风险的影响比较
- Author:
Jinping SHI
1
;
Yajuan TANG
;
Yan ZHANG
;
Hongbing LI
;
Juan BAI
;
Shuxia HONG
Author Information
1. 西安国际医学中心医院药学部，西安 710100
- Keywords:
Atrial fibrillation;
Anticoagulants;
Rivaroxaban;
Amiodarone;
Hemorrhage;
Drug interactions
- From:
Chinese Journal of Primary Medicine and Pharmacy
2024;31(5):742-746
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the influence of dronedarone and amiodarone on the bleeding risk of patients with atrial fibrillation treated with rivaroxaban anticoagulation.Methods:Clinical data of 81 patients with atrial fibrillation treated with rivaroxaban anticoagulation at Xi'an International Medical Center Hospital from January 2020 to July 2023, including 36 patients treated with dronedarone and 45 patients treated with amiodarone, were retrospectively analyzed. The effects of dronedarone and amiodarone on the anticoagulation of rivaroxaban were compared using the incidence of bleeding events, thrombosis events, and adverse reactions as outcome measures.Results:The total bleeding in the dronedarone group [22.22% (8/36)] was significantly higher than that in the amiodarone group [6.67% (3/45)] ( χ2 = 4.12, P < 0.05). The total bleeding of conventional-dose rivaroxaban in the dronedarone group was 30.00% (6/20), while the total bleeding of low-dose rivaroxaban was 12.50% (2/16), with no statistical significance ( χ2 = 1.58, P > 0.05). No thrombotic events or adverse reactions to dronedarone or amiodarone were observed in all patients. Conclusion:Compared with amiodarone, dronedarone significantly increases the bleeding risk of rivaroxaban anticoagulation in patients with non-valvular atrial fibrillation, and reducing the dose of rivaroxaban in patients using dronedarone does not reduce the bleeding risk.
